Serial change in serum KL-6 levels correlate with the pulmonary function variables in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011
Could KL-6 levels in COVID-19 help to predict lung disease ? Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021
High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008
KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
Correlation of HRCT proven inflammatory changes with serum levels of ACE, sIL-2r and calciuria in pulmonary sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Serum KL-6 and SP-D as useful clinical indicators of interstitial changes and pulmonary functional abnormality in patients with Sjogren's syndrome Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001
Annual changes of serum KL-6 were inversely correlated with those of respiratory function parameters in patients with nonspecific interstitial pneumonia Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
High serum CA-125 level in active pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 415s Year: 2005
Early stage asymptomatic (HRCT detectable) patients with IPF showed augmented serum surfactant protein D (SP-D) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020